Synbio Tech Inc., a Taiwanese biotechnology firm, is set to gain international attention with its innovative probiotic strain, Lactiplantibacillus plantarum TWK10®. This clinically validated strain will be showcased at SupplySide Global 2025, taking place from October 27 to 30 in Las Vegas.
TWK10® has demonstrated significant benefits in enhancing muscle strength, endurance, and balance, providing a novel microbiome-based strategy for promoting healthy aging and active lifestyles. With over ten years of research backing it, this probiotic strain has undergone rigorous evaluation in peer-reviewed clinical studies. The results indicate that TWK10® can improve endurance performance by 20-40% and increase muscle mass by 0.5-1 kg, while also enhancing overall strength, recovery, and mobility for individuals at various life stages.
One notable study involving TWK10® was recognized by Wiley as a “Top Cited Article,” highlighting its scientific significance and impact on research related to the gut-muscle axis. The strain has received strong recognition and credibility from multiple global regulatory bodies, including achieving U.S. GRAS Self-Affirmed status, Health Functional Food approval in Korea, and certification as a health food in Taiwan with an anti-fatigue claim. Additionally, it has been registered in Malaysia and listed as a probiotic in Thailand. A recent authorization in Japan further solidifies TWK10® as one of the most clinically and regulatory validated probiotics for muscle health worldwide.
These accomplishments, coupled with a growing repository of real-world data, reinforce SynbioTech”s position as a science-driven innovator in the field of microbiome health solutions, utilizing both probiotics and postbiotics. “For SynbioTech, it”s more than a product story—it”s about demonstrating how microbiome science can genuinely enhance daily life,” stated Chuan-Hsien Yang, the company”s Chief Operating Officer. “TWK10® is the culmination of years of research that integrates traditional fermentation techniques from Taiwan with contemporary clinical science.”
As SynbioTech continues to broaden its global partnerships and research collaborations, it aims to connect Asian innovations with markets around the world, empowering individuals to lead healthier lives through advancements in microbiome science.
Founded in 2000, Synbio Tech specializes in probiotics, postbiotics, and microbiome-based health solutions. With over 25 years of research and development expertise and a fully integrated contract development and manufacturing organization (CDMO) platform, the company collaborates with more than 600 brands across 35 countries to deliver innovative solutions that significantly impact health through probiotics.
